Cargando…
Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study
Introduction Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique geographical distribution. It is prevalent in East and Southeast Asia and rare in non-endemic countries like the USA. P16 is a tumor suppressor gene and there are limited studies with inconsistent results describing the ass...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042511/ https://www.ncbi.nlm.nih.gov/pubmed/36994280 http://dx.doi.org/10.7759/cureus.35308 |
_version_ | 1784912951823564800 |
---|---|
author | Ghimire, Bipin Trentacosta, Emma Thapa, Shrinjaya Karki, Ujjwal Nwabundo, Anusim Wang, Can Poudel, Shyam K George, Julie Jaiyesimi, Ishmael |
author_facet | Ghimire, Bipin Trentacosta, Emma Thapa, Shrinjaya Karki, Ujjwal Nwabundo, Anusim Wang, Can Poudel, Shyam K George, Julie Jaiyesimi, Ishmael |
author_sort | Ghimire, Bipin |
collection | PubMed |
description | Introduction Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique geographical distribution. It is prevalent in East and Southeast Asia and rare in non-endemic countries like the USA. P16 is a tumor suppressor gene and there are limited studies with inconsistent results describing the association of its positivity in immunohistochemistry and clinical outcomes. In this retrospective study, we compared progression-free survival (PFS) and overall survival (OS) based on p16 positivity in 60 patients with NPC. Materials and methods Patients aged above 18 years and followed between July 2015 and December 2020 were included in the study. P16 positivity was based on the immunohistochemistry of the biopsy sample. We compared PFS and OS among all p16-positive and negative patients, and then among patients with advanced disease (stage III or IV), and between p16-positive, negative, and unknown status patients. Results There were 15 p16-positive, and 28 p16-negative, with a median age of 54.3 years and 55.7 years respectively. Most patients in both groups were male, Caucasian, and had advanced disease (stage III or stage IV). Both median PFS (p=0.838) and OS (p=0.776) were 84 months in the p16-negative group but were not reached during the study period in the p16-positive group. Among advanced-stage patients, the PFS (p=0.873), and OS (p=0.773) of both groups were not statistically significant. P16 status was unknown for 17 patients, and PFS (p=0.785) and OS (p=0.901), when compared among patients with p16-positive, negative, and unknown status, were also statistically non-significant. Discussion and conclusion Our analysis suggests that p16 status does not predict clinical outcomes in NPC patients. Our sample size was limited but is larger than most studies describing this association. With different studies in the literature reporting disparate findings, we recommend larger prospective studies to better illustrate the impact of p16 positivity on clinical outcomes in NPC. |
format | Online Article Text |
id | pubmed-10042511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-100425112023-03-28 Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study Ghimire, Bipin Trentacosta, Emma Thapa, Shrinjaya Karki, Ujjwal Nwabundo, Anusim Wang, Can Poudel, Shyam K George, Julie Jaiyesimi, Ishmael Cureus Otolaryngology Introduction Nasopharyngeal carcinoma (NPC) is a rare malignancy with unique geographical distribution. It is prevalent in East and Southeast Asia and rare in non-endemic countries like the USA. P16 is a tumor suppressor gene and there are limited studies with inconsistent results describing the association of its positivity in immunohistochemistry and clinical outcomes. In this retrospective study, we compared progression-free survival (PFS) and overall survival (OS) based on p16 positivity in 60 patients with NPC. Materials and methods Patients aged above 18 years and followed between July 2015 and December 2020 were included in the study. P16 positivity was based on the immunohistochemistry of the biopsy sample. We compared PFS and OS among all p16-positive and negative patients, and then among patients with advanced disease (stage III or IV), and between p16-positive, negative, and unknown status patients. Results There were 15 p16-positive, and 28 p16-negative, with a median age of 54.3 years and 55.7 years respectively. Most patients in both groups were male, Caucasian, and had advanced disease (stage III or stage IV). Both median PFS (p=0.838) and OS (p=0.776) were 84 months in the p16-negative group but were not reached during the study period in the p16-positive group. Among advanced-stage patients, the PFS (p=0.873), and OS (p=0.773) of both groups were not statistically significant. P16 status was unknown for 17 patients, and PFS (p=0.785) and OS (p=0.901), when compared among patients with p16-positive, negative, and unknown status, were also statistically non-significant. Discussion and conclusion Our analysis suggests that p16 status does not predict clinical outcomes in NPC patients. Our sample size was limited but is larger than most studies describing this association. With different studies in the literature reporting disparate findings, we recommend larger prospective studies to better illustrate the impact of p16 positivity on clinical outcomes in NPC. Cureus 2023-02-22 /pmc/articles/PMC10042511/ /pubmed/36994280 http://dx.doi.org/10.7759/cureus.35308 Text en Copyright © 2023, Ghimire et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Otolaryngology Ghimire, Bipin Trentacosta, Emma Thapa, Shrinjaya Karki, Ujjwal Nwabundo, Anusim Wang, Can Poudel, Shyam K George, Julie Jaiyesimi, Ishmael Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title | Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title_full | Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title_fullStr | Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title_full_unstemmed | Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title_short | Impact of P16 Positivity on Clinical Outcomes in Nasopharyngeal Carcinoma: A Single Institution Study |
title_sort | impact of p16 positivity on clinical outcomes in nasopharyngeal carcinoma: a single institution study |
topic | Otolaryngology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042511/ https://www.ncbi.nlm.nih.gov/pubmed/36994280 http://dx.doi.org/10.7759/cureus.35308 |
work_keys_str_mv | AT ghimirebipin impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT trentacostaemma impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT thapashrinjaya impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT karkiujjwal impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT nwabundoanusim impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT wangcan impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT poudelshyamk impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT georgejulie impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy AT jaiyesimiishmael impactofp16positivityonclinicaloutcomesinnasopharyngealcarcinomaasingleinstitutionstudy |